Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jeffrey W Jansen"'
Publikováno v:
Infectious Diseases in Clinical Practice. 31
Autor:
Taylor M. Brisben, Cody R. Maldonado, Michaela M. Bruner, Rachel L. Ott, Sarah K. Spilman, Jeffrey W. Jansen
Publikováno v:
Journal of Pharmacy Practice and Research.
Publikováno v:
Annals of Pharmacotherapy. 51:543-547
Background: New hepatitis C virus (HCV) therapies report cure rates of ~90% but are expensive. Identification of predictors for treatment failure could help decrease health care costs, limit unnecessary drug exposure and adverse events, and prevent d
Publikováno v:
Open forum infectious diseases. 6(7)
Background Little information is available on the relative tolerability of ceftaroline versus other cephalosporins in clinical practice. We sought to compare adverse drug reactions (ADRs) associated with ceftaroline with those associated with ceftria
Publikováno v:
Open Forum Infectious Diseases
Background Hepatitis C remains a major cause of liver disease globally and is responsible for approximately 500 000 deaths annually. Newer direct-acting antivirals achieve cure rates at or above 90% with excellent tolerability for most patients. The
Autor:
Riley Grubbs, Kristin Dimond, Forrest Murter, Jeffrey W Jansen, Clark Vowell, Cody Maldonado, Christopher Gilstrap
Publikováno v:
Open Forum Infectious Diseases
Background Community-acquired pneumonia (CAP) is the leading infectious cause of death and severe sepsis in the United States and the fifth leading cause of death overall worldwide. Current United States guidelines for the treatment of CAP recommend
Autor:
Jeffrey W Jansen, Ryan P Moenster
Publikováno v:
The Annals of pharmacotherapy. 52(3)
Background: Ceftaroline is a broad-spectrum, methicillin-resistant Staphylococcus aureus (MRSA)-active β-lactam approved for acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia. Because of its favorable spec
Publikováno v:
Open Forum Infectious Diseases
Voriconazole, a broad-spectrum antifungal, has been associated with visual and auditory hallucinations. We report the case of patient being treated with voriconazole for pulmonary aspergillosis who developed visual hallucinations and new suicidal ide
Autor:
Jeffrey W. Jansen
Publikováno v:
Clinical Infectious Diseases. 64:1292-1293
Publikováno v:
Open Forum Infectious Diseases
Background At the VA St. Louis Health Care System 17.3% of patients treated with ceftaroline developed an adverse drug reaction (ADR). This evaluation compares ADR rates between patients treated with ceftaroline and those treated with ceftriaxone. Me